{
    "nct_id": "NCT04965454",
    "official_title": "Clinical Trial of Biomarkers for Predicting Immunotherapy Response in Hepatocellular Carcinoma",
    "inclusion_criteria": "* Age 18 years or older (no upper limit of age)\n* Hepatocellular carcinoma diagnosis made histologically or radiographically in accordance to National Comprehensive Cancer Network guidelines (3.2019 version or higher)\n* Does not qualify for surgical resection or locoregional therapy alone or has disease that has progressed after surgical resection and/or locoregional therapy\n* Has measurable disease defined as at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 on CT/MRI completed within past 6 weeks of eligibility screening\n* Under the care of a licensed medical oncologist\n* Life expectancy > 6 months\n* Deemed eligible for treatment with an immune checkpoint inhibitor agent based on the treating medical oncologist's assessment of previous treatment failure, clinical/performance/virology status, and liver/renal/hematologic function.\n* Child-Pugh score of 9 or less\n* Creatinine clearance ≥ 40 mL/min, measured or calculated using the Cockcroft-Gault formula\n* ALT and AST ≤7x upper limit of normal\n* Total bilirubin ≤4 mg/dL\n* Albumin ≥2.8 g/dL\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Weight > 500 lbs (PET/CT limit)\n* Pregnant or lactating female (those of child-bearing potential must be re-screened within 7 days prior to PET/CT imaging)\n* Serious underlying medical condition that would impair patient's ability to tolerate the imaging procedure\n* Concurrent treatment with a non-targeted therapeutic agent. Concurrent enrollment in an ICI-treatment trial and combination ICI treatment are allowed.",
    "miscellaneous_criteria": ""
}